Serious adverse reactions (SAR) and

suspected unexpected serious adverse reactions (SUSAR)

**PART 1:** SAR and SUSAR (from investigator to Sponsor)

**PART 2:** SUSARs (Sponsors assessment)

**Protocol title: Agents Intervening against Delirium in the Intensive Care Unit (AID-ICU)**

EudraCT number: 2017-003829-15

Protocol number: SJ-646

**PART 1 (To be filled in by Investigator)**

**Report date** (dd-mm-yyyy)**:**

**Report type**

 Initial [ ]  Follow up [ ]

**Participant information**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Patient initials | Country | Date of birth (dd-mm-yyyy)  | SexM [ ]  F [ ]  | Height:Weight: |
| Trial participant ID | Name of site |

**Serious Adverse Reactions (SARs)**

A SAR is life-threatening, requires hospitalisation or prolongation of existing hospitalisation or results in persistent or significant disability or incapacity. See definition of SARs in the AID-ICU trial at next page.

If a SAR occurs please remember to

1) discontinue the trial medication

2) continue to fill in day forms

|  |  |
| --- | --- |
| SAR onset date (dd-mm-yyyy) | SAR end date (dd-mm-yyyy) |
| Patient discontinued from study drug due to SAR Yes [ ]  → date (dd-mm-yyyy): time (hh:mm): No [ ]   |

|  |  |
| --- | --- |
| **Type of reaction** | **Mark** |
| **Anaphylactic reaction related to the intervention***Definition: urticaria and a least one of the following:* *1. Worsened circulation (>20% decrease in blood pressure or >20% increase in vasopressor dose)**2. Increased airway resistance (>20 % increase in the peak pressure on the ventilator)* *3.Clinical stridor or bronchospasm* *4.Subsequent treatment with bronchodilators* |[ ]
| **Agranulocytosis related to the intervention***Definition: any new, acute and severe drop in granulocytes to <0.5 x 109/l requiring active monitoring or treatment*  |[ ]
| **Pancytopenia related to the intervention***Definition: any new, severe drop in red blood cells (as severe anaemia, b-Hgb < 4.3mM), white blood cells* *(< 0.5 x 109/l) and platelets (< 20 x 109/l) requiring active monitoring or treatment* |[ ]
| **Acute hepatic failure related to the intervention***Definition: severe and progressing acute hepatic failure as judged by the treating doctor or the investigator* |[ ]
| **Tardive dyskinesia or other extrapyramidal symptoms (EPS) related to the intervention***Definition: any of following symptoms:**Tardive dyskinesia (rhythmical involuntary movements of tongue, face, mouth or jaw), dystonia (continuous spasm and muscle contractions), akathisia (motor restlessness) or parkinsonism (characteristic symptoms such as rigidity, bradykinesia and tremor)**Mild forms of tremor or akathisia are NOT considered a SAR.* |[ ]
| **Neuroleptic malignant syndrome related to the intervention***Definition: Hyperpyrexia, severe muscle rigidity and catatonia or autonomic instability (tachycardia, diaphoresis, incontinence, dysphagia, cardiac dysrhythmias or irregular pulse/blood pressure) that cannot be explained by other aetiology* |[ ]
| **Type of reaction** | **Mark** |
| **Ventricular arrhythmia related to the intervention***Definition: any first onset of ventricular arrhythmia (except PVCs) seen on ECG or continuous cardiac monitoring* |[ ]
| **Reaction not described above but related to the intervention (unsuspected)** *please specify* |[ ]

**Evaluation of SAR**

|  |  |  |
| --- | --- | --- |
| **Outcome** |  |  |
| Ongoing reaction |[ ]   |
| Resolved |[ ]   |
| Fatal |[ ]   |
| Unknown |[ ]   |

**Death**

|  |  |
| --- | --- |
| Date of death (dd-mm-yyyy) | Cause of death |

Relationship of the event and study drug

|  |  |
| --- | --- |
|  Unrelated to the study drug [ ]  (No, unlikely) |  Related to the study drug [ ]   (Possible, probable, definite) |

Drug information

|  |  |
| --- | --- |
| Batch no: | Did the reaction abate after discontinuing the trial medication?  Yes [ ]  No [ ]  NA [ ]   |

Event Description

Concomitant medication(s) relevant to the event (exclude those used to treat the event)

|  |
| --- |
| Concomitant drug(s) and dates (dd-mm-yyyy) of administration. |

Reporter information Investigator information

|  |  |
| --- | --- |
| Name: | Name: |
| Address: | Address: |
| Phone:+ | Phone:+ |
| Profession: | Profession: |
| Signature & date (dd-mm-yyyy) | Signature & date (dd-mm-yyyy) |

Fill in this form and e-mail it to the coordinating centre

**E-mail:** aid-icu@cric.nu

**Sponsors signature for receiving this report**:

Date: \_\_\_\_\_\_\_\_\_\_\_ Signature: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**PART 2: (To be filled in by sponsor)**

Causality assessment by Sponsor:

**1. Result of causality evaluation**

[ ]  Not related to study drug (Unlikely/doubtful) → (If not judged related, please comment in box 4)

[ ]  Related to study drug (Possible/Probable/Definite) → (Go to box 2 below)

**Expectedness** **assessment by Sponsor (only relevant if the SAR is related to the study drug):**

**2. Result of the expectedness evaluation**

[ ]  Expected (due to relevant reference document)

[ ]  Unexpected→ (Go to box 3 below)

**Summary:**

**3. Category of event**

[ ]  SUSAR (SAR is both related and unexpected)

[ ]  SAR (SAR is related but not unexpected)

**Notify relevant authorities according to the protocol**

Sponsors comments (including information regarding unblinding):

**4.**

**Sponsors signature**:

Date: \_\_\_\_\_\_\_\_\_\_\_ Signature: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_